All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At ASCO 2019, Chicago, US, the Multiple Myeloma Hub were delighted to interview Jonathan L. Kaufman, Winship Cancer Institute of Emory University, Atlanta, US, about the safety and efficacy of the D-Rd regimen; daratumumab + lenalidomide + dexamethasone.
The POLLUX study, recruited patients with relapsed/refractory multiple myeloma. This is an updated analysis, focusing on cytogenetics. The results found that high-risk patients significantly benefited from the addition of daratumumab to lenalidomide + dexamethasone. This was also seen in the standard-risk group indicating all cytogenetics subgroups benefited.
Safety and efficacy of D-Rd in R/R multiple myeloma
Subscribe to get the best content related to multiple myeloma delivered to your inbox